Health
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
BOSTON, May 18, 2026--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication.
About this update from Stryker Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/3a7cf9134c27f8685bd279fb0320b88c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oyKnHYlBgPGIISDit0xmxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNA--/https://media.zenfs.com/en/business-wire.com/3a7cf9134c27f8685bd279fb0320b88c","width":480,"height":212},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/trcO4y31aobLfcye8V1_BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI4Mw--/https://media.zenfs.com/en/business-wire.com/3a7cf9134c27f8685bd279fb0320b88c","width":480,"height":212}},"lazy":false},{"type":"text","content":"POWER CAD I study will evaluate feasibility of the Pulse IVL™ system in patients with severely calcified coronary arterial disease","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 18, 2026--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication.","length":354,"tagName":"p"},{"type":"text","content":"The POWER CAD I study will evaluate the feasibility of the Pulse IVL™ System for the treatment of patients with moderate to severely calcified coronary arterial disease. Dr. Jithendra Somaratne, interventional cardiologist at Auckland City Hospital and The Heart Group in Auckland, New Zealand, conducted the first case. The study will enroll up to 15 subjects at up to four facilities in Australia and New Zealand, with primary endpoints assessed at 30 days.","length":459,"tagName":"p"},{"type":"text","content":""AVS is the only intravascular lithotripsy company to utilize a unique hydraulic mechanism of action, and this is the first step in understanding the patient population that may be able to benefit from our innovative technology," said Tim Lanier, President, Stryker’s Peripheral Vascular division. "This marks a significant clinical milestone for us as we aim to expand the application of our technology to coronary disease. We are confident our Pulse IVL system, which is designed for easy delivery and effi...